Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Efficacy of xeno-free induced mesenchymal stem/stromal cells in enhancing autologous fat graft survival.

Nakamura H., Makiguchi T., Yamaguchi T., Kurozumi S., Kamiya D., Ikeya M.

Animal Study on Immune Modulation, published in Breast Cancer (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Breast Cancer (2026)
Country
Japan
Reported sample size
—
Source database
PubMed
PMID
41729432
PMCID
PMC13124772
DOI
10.1007/s12282-026-01838-3

Abstract (original English)

BACKGROUND: Breast reconstruction using autologous fat grafting offers a less invasive alternative with shorter surgical times compared to traditional flap procedures. Although adipose-derived stem cells (ASCs) have improved fat graft survival rates, the variability in mesenchymal stem cells (MSCs) quality due to donor health and medication intake poses challenges. MSCs derived from induced pluripotent stem cells (iPSC-MSCs) demonstrate enhanced proliferative and immunomodulatory properties that may further enhance outcomes. METHODS: We harvested human adipose tissue from surgical specimens and isolated ASCs. We used human iPSC-MSCs generated through a neural crest cell lineage under xeno-free conditions (iMSCs), to assess the improvement in survival and integration of autologous human adipose tissue grafts in BALB/c-nu/ + mice. We compared outcomes in groups treated with phosphate-buffered saline (PBS), ASCs, and iMSCs over 28 days, focusing on fat graft retention, fibrosis, and neovascularization, and adipogenic differentiation using vimentin/perilipin immunofluorescence staining. RESULTS: iMSC treatment significantly preserved graft area (82.3 ± 20.5%) compared to PBS controls (50.6 ± 28.7%) and ASC treatments (65.3 ± 24.7%). It also resulted in the lowest fibrosis (7,748.7 ± 6,018.6 µm2) and highest neovascularization (68,681.5 ± 21,363.4 µm2), indicating improved tissue in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAnimalsAdipose TissueMesenchymal Stem CellsGraft SurvivalFemaleMiceMesenchymal Stem Cell TransplantationCell DifferentiationInduced Pluripotent Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research